Submission of voting results and scrutinizer''s report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (BSE: 536565) held its 31st AGM on September 19, 2025, via video conferencing. Out of 2,776 shareholders on the record date (September 12, 2025), 81 attended through VC (2 promoter group, 79 public), and about 77.5% of outstanding shares (10,029,122 of 12,935,000) were voted. All 9 resolutions passed with near-unanimous support (~99.9999% in favor). These included ordinary resolutions for adopting FY25 financial statements, re-appointing Mr. Jivamohan Divakar Valluri as a non-executive director, appointing M/s. Khushbu Kanwar & Co. as secretarial auditors, and appointing Mr. Gattu Gnana Prakash as a non-executive non-independent director. Special resolutions approved increasing the borrowing limit under Section 180(1)(c), creation of mortgage/charge on assets under Section 180(1)(a), investments/loans/guarantees under Section 186, transactions under Section 185, and the appointment of Ms. Mayuri Baidya as an independent director. The scrutinizer (Bharat Khaniwal & Co.) certified the results.
All items were routine AGM business and passed with overwhelming shareholder support, so this filing is unlikely to move the stock meaningfully on its own. However, the special resolutions give the board wider room to raise debt, pledge assets, and extend loans or guarantees, which signals potential fundraising or expansion activity ahead.